Pharmacokinetics of Intravenous Acyclovir, Zidovudine, and 
Acyclovir-Zidovudine in Pregnant Rats
Stacy D. Brown, Michael G. Bartlett, and Catherine A. White*

Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, The University of 
Georgia, Athens, Georgia 30602-2352

Received 5 August 2002/Returned for modification 8 October 2002/Accepted 19 December 2002

The pharmacokinetics and placental transfer of acyclovir and zidovudine monotherapies and acyclovir-
zidovudine combination therapy were compared in the pregnant rat. Timed-pregnancy Sprague-Dawley rats were 
used for the study. Doses of 60 mg of each drug/kg of body weight in monotherapy and in combination 
therapy were given by intravenous bolus, and samples of maternal plasma, amniotic fluid, fetal tissue, and 
placental tissue were collected over a period of 8 h postdose. Concentrations of each drug in the various 
matrices were measured by high-performance liquid chromatography. All data were analyzed by using Win-
Nonlin. A one-compartment model with first-order elimination was used to fit the AZT plasma data from the 
combination therapy rats, but the plasma data from the other groups were fit to a two-compartment model. 

Tissue data were analyzed by noncompartmental analysis to generate area-under-the-concentration-time-curve 
values. Implementation of the combination therapy altered the pharmacokinetics of each drug compared to its 
monotherapy pharmacokinetics. The combination of these two drugs may potentiate fetal and amniotic fluid 
exposures to each drug.

Acyclovir (9-[(2-hydroxyethoxy)-methyl]-guanosine [ACV]), an acyclic analog of the natural nucleoside 2’-deoxyguanosine (Fig. 1), is active against the members of the herpes group of 
DNA viruses (14, 42). For over 2 decades, ACV has been considered the first choice of treatment for herpes simplex 
virus types 1 and 2 (HSV-1 and -2), but it has also been shown to effectively treat varicella-zoster virus and provide protection 
from cytomegalovirus in immunosuppressed patients receiving 
thanhrips (12, 32). The success of ACV in treating HSV has 
prompted the synthesis of several structural analogs, but none 
has shown to be as tolerable as and have shown to have such a 
high therapeutic index as ACV (13, 35, 40). Zidovudine (3’-
azido-3’-deoxythymidine [AZT]) (Fig. 1) is the premier reverse 
transcriptase inhibitor released for the treatment of human 
immunodeficiency virus (HIV). A therapy involving the 
combination of ACV and AZT is not uncommon to help suppress 
symptoms in patients who are both HIV positive and HSV-2 positive. These drugs, both in monotherapy and in combination, 
have been used to prevent vertical (mother-to-child) transmission of HSV-2 and HIV.

The Acyclovir in Pregnancy Registry has compiled a large 
amount of case study information regarding the relative safety 
and efficacy of ACV use in HSV-2-positive pregnant women 
(1). Although a great deal is known about the pharmacokinetic 
properties of ACV, little work has been done to characterize 
the placental transfer of ACV in vivo, because pregnant 
women are routinely excluded from clinical trials. Pharcmo-
kineic parameters may be altered during pregnancy due to the 
increase in body fat content, cardiac output, and total body 
water seen in pregnant women (15, 41, 48). There may also be 
changes in plasma albumin concentration and protein binding 
affinities (25, 39). The perfused human placenta model has 
been used on occasion in attempts to characterize the placental 
transfer of ACV (21, 24). However, this type of model does not 
mimic the dynamic among fetus, amniotic fluid, and placenta 
that exists in the whole animal. Unlike ACV, AZT is approved 
by the Food and Drug Administration for use during preg-
nancy. To date, several groups have investigated the placental 
transfer of AZT monotherapy by using animal or in vitro 
models (20, 22, 26, 30, 38). Huang et al. developed a compart-
mental pharmacokinetic model for the pregnant rat that de-
scribed AZT distribution in all matrices associated with preg-
nancy (maternal plasma, amniotic fluid, placenta, and fetal 
tissue) (26). The consensus concerning AZT behavior in preg-
nancy is that it readily crosses the placenta via passive diffusion 
(20, 22, 26, 38).

The pregnant rat model has been used successfully in the 
study of the placental transfer of many compounds, including 
nucleoside analogs (2–4, 9, 11, 18, 23, 26–28, 36, 37, 46). The 
hemodynamic changes present in the pregnant rat are similar 
to those seen in a human pregnancy (3, 16). The pregnant rat 
model is also ideal for pharmacokinetic studies because of the 
short gestation time and the containment of each fetus, pla-
centa, and amniotic fluid in individual fetal sacs that allows for 
concurrent serial sampling of the pups.

The pregnant rat model has been used successfully in the 
study of the placental transfer of many compounds, including 
nucleoside analogs (2–4, 9, 11, 18, 23, 26–28, 36, 37, 46). The 
hemodynamic changes present in the pregnant rat are similar 
to those seen in a human pregnancy (3, 16). The pregnant rat 
model is also ideal for pharmacokinetic studies because of the 
short gestation time and the containment of each fetus, pla-
centa, and amniotic fluid in individual fetal sacs that allows for 
concurrent serial sampling of the pups.

To date, the effect of pregnancy on the placental transfer of 
ACV has not been investigated and limited data are available 
on the influence of pregnancy on the pharmacokinetics of 
ACV (29). Although antiviral combinations are often admin-
istered to pregnant women, the pharmacokinetic changes 
associated with each individual drug have not been studied under 
these circumstances. A study of the safety and efficacy of AZT 
with and without ACV found no changes in the efficacy of the 
drugs and no indication of renal dysfunction or hepatotoxicity 
associated with the drugs given in combination (10). Cooper et
al. also found that, when ACV and AZT were given together, the HIV-induced cytopathic effect was increased two- to threefold over that found in AZT monotherapy (10). Mamede et al. showed that this drug combination did not lower the birth weights of rats but rather that the combination showed a protective effect against the low birth weights seen in ACV monotherapy (31). This study examines the pharmacokinetics of ACV and AZT monotherapy and ACV-AZT combination therapy during pregnancy by using the same doses as did Mamede et al. (31).

MATERIALS AND METHODS

Reagents and chemicals. Analytical standards of ACV, ganciclovir, and AZT were obtained from Sigma (St. Louis, Mo.). 3'-Azido-2',3'-dideoxythymidine (AZT) and the internal standard, ganciclovir, were purchased from Enzo Life Sciences (Farmington, Conn.). HPLC-grade acetonitrile and methanol and agent-grade ammonium acetate and reagent-grade octanesulfonic acid were purchased from Fisher Scientific (Fair Lawn, N.J.). Sep-Pak Vac 1-ml C18 cartridges were purchased from Waters (Milford, Mass.). The deionized water used was generated from a Continental Deionized Water System (Natick, Mass.). 3'-dideoxythymidine (3TC), also an internal standard, was recrystallized from Epivir tablets. Reagent-grade citric acid was acquired from Sigma. Reagents and chemicals were obtained from Sigma (St. Louis, Mo.). The average weight of 331 ± 20 g was controlled, with 14 h of light per day, a constant temperature of 20 to 22°C, daily feedings of standard chow, and water ad libitum.

Animal study. The use of animals for this study was approved by the University of Georgia Animal Use and Care Committee and was conducted in accordance with the Animal Welfare Act and the National Institutes of Health Guide for the Care and Use of Laboratory Animals. The rats were housed one animal per cage in the University of Georgia College of Pharmacy Association for Assessment of Laboratory Animal Care-accredited animal facility. The living environment of the animals was controlled, with 14 h of light per day, a constant temperature of 20°C until analysis.

HPLC analysis and ACV monotherapy. The plasma and amniotic fluid samples were prepared by acid protein precipitation by adding 10 μl (50-μl amniotic fluid sample) or 20 μl (100-μl plasma sample) of 2 M perchloric acid. Placental and fetal tissue homogenates were processed by solid-phase extraction by using Waters Sep-Pak Vac C18 SPE cartridges. The solid-phase extraction procedure included a conditioning step with methanol and the mobile phase, followed by the sample load and a wash of the sample with deionized water and finally an elution with methanol. The internal standard, ganciclovir, was also spiked into each sample to yield a final ganciclovir concentration of 10 μg/ml in the sample. Calibration curves were generated by using samples from spiked blank matrix to yield final calibration points of 0.1, 0.5, 1, 5, 10, 50, and 100 μg/ml. The chromatographic system consisted of a Hewlett-Packard (Agilent) 1100 Series HPLC with a quaternary pump, degasser, autosampler, and variable-wavelength UV detector (Palo Alto, Calif.). Chromatographic separations were achieved by using an Agilent Eclipse XDB C-8 column (150 by 2.1 mm, 5 μm) with a Phenomenex Security Guard C18 guard column (Torrance, Calif.).

The mobile phase used for the plasma and amniotic fluid matrices was a 10 mM acetate-citrate buffer:5.7 mM aqueous octanesulfonic acid (87:12.5 [vol/vol]) adjusted to pH 3.08 with phosphoric acid. Under these conditions, ganciclovir eluted at ≈8 min and ACV eluted at ≈11 min. The mobile phase used for the placental and fetal tissue samples was a 30 mM acetate-citrate buffer with 5 mM octanesulfonic acid (pH 3.08) and acetonitrile (99:1 [vol/vol]). Under these conditions, ganciclovir eluted at ≈10 min and ACV eluted at ≈12 min.
conditions, ganciclovir eluted at ~10 min and ACV eluted at ~12 min. All flow rates were kept at a constant 0.200 ml/min, the injection volume used was 10 μl, and the detection wavelength was fixed at 254 nm. This method has been previously validated to show acceptable precision and accuracy for the quantitation of ACV in the range of 0.1 to 100 μg/ml.

**HPLC analysis and AZT monotherapy and ACV-AZT combination therapy.** Sample preparation for plasma and all tissues is as described above. 3TC was spiked into each plasma and amniotic fluid sample (25 μg/ml) to serve as an internal standard. Because of the chromatographic interference of endogenous peaks, 3TC could not be used as an internal standard for the placental and fetal tissues and was replaced by AZDU. AZDU was spiked into each placenta and fetal tissue sample at a level of 10 μg/ml. Calibration curves were generated by using a spiked blank matrix to yield final calibration points of 0.1, 0.5, 1, 5, 10, 50, and 100 μg/ml.

The HPLC system used in this assay is the same as described above. Because of the relative differences in the polarities of ACV and AZT, a gradient elution technique had to be utilized for timely analysis. The mobile phase consisted of a 30 mM acetate-citrate buffer at pH 3.08 (component A) and methanol (component B). Under these conditions, ACV eluted at 7.6 min, AZT at 15.9 min, and 3TC at 10.9 min in the plasma and amniotic fluid. In the fetus and placental tissues, ACV eluted at 7.4 min, AZT at 19.8 min, and AZDU at 18.4 min. This assay was validated to ensure both precision and accuracy in accordance with the Food and Drug Administration guidelines for bioanalytical method validation (43). The assay showed acceptable reproducibility (per cent relative standard deviation < 15%) and accuracy (per cent error < 15%) over the calibration range of 0.1 to 100 μg/ml.

**Data analysis.** When WinNonlin was used, the plasma data from all rats were subjected to compartmental analysis. A two-compartment intravenous bolus model with first-order elimination was used to fit the plasma data generated from AZT monotherapy-dosed rats and ACV for both monotherapy and combination therapy animals. However, the plasma distribution phase for AZT in the combination therapy animals was not observed; therefore, a one-compartment intravenous bolus model with first-order elimination was used to fit the AZT plasma data from the combination therapy animals. A 1/y weighting scheme was used throughout the analysis. Amniotic fluid, fetus, and placenta were subjected to noncompartmental analysis, and the area under the concentration-time curve (AUC) was truncated at 8 h due to the inability of calculate an accurate elimination half-life for all tissues and amniotic fluid. To express relative exposure to each matrix, the AUC values for the individual tissues were compared to the AUC (0 to 8 h) values for the corresponding plasma data. The pharmacokinetic parameters generated for each dosing group and the relative exposure numbers were compared by using the unpaired t test (P < 0.05) to detect statistically significant differences.

**RESULTS AND DISCUSSION**

The fitted concentration in plasma-time profiles from a representative animal for AZT and ACV are shown in Fig. 2. The pharmacokinetic parameters generated from the compartmental analysis of the plasma data are presented in Table 1. Co-administration of ACV resulted in a 60% decrease in total clearance of AZT. Considering that renal excretion is the major route of elimination for both drugs in rats and that ACV and AZT are both transported by the organic anion transporter, this decrease in clearance is probably due to the inhibition of active tubular secretion in the kidney (35, 37). A significant increase in both half-life and AUC for AZT was also

![Graph](https://example.com/graph.png)

**FIG. 3.** Concentration (mean plus standard deviation) versus time profiles of AZT monotherapy and in combination with ACV from amniotic fluid (a), fetus (b), and placenta (c).

**TABLE 1.** Pharmacokinetic parameters (mean plus or minus standard deviation) generated from the compartmental analysis of plasma data collected from pregnant ACV monotherapy, AZT monotherapy, and ACV-AZT combination therapy rats (60 mg/kg).

<table>
<thead>
<tr>
<th>Drug therapy</th>
<th>Half-life (h)</th>
<th>AUC (h·mg/liter)</th>
<th>Clearance (liter/h·kg)</th>
<th>V_{ss} (liter/kg)</th>
<th>C_{max} (mg/liter)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACV</td>
<td>9.12 ± 1.1</td>
<td>467 ± 183</td>
<td>0.14 ± 0.05</td>
<td>1.61 ± 0.26</td>
<td>148.4 ± 88</td>
</tr>
<tr>
<td>ACV-AZT</td>
<td>2.48 ± 1.9*</td>
<td>241 ± 165*</td>
<td>0.34 ± 0.2*</td>
<td>0.80 ± 0.1*</td>
<td>196.7 ± 27</td>
</tr>
<tr>
<td>AZT</td>
<td>1.39 ± 0.3</td>
<td>80 ± 21</td>
<td>0.78 ± 0.2</td>
<td>1.52 ± 0.42</td>
<td>72.1 ± 14</td>
</tr>
<tr>
<td>AZT-ACV</td>
<td>2.69 ± 1.2*</td>
<td>240 ± 130</td>
<td>0.31 ± 0.2*</td>
<td>1.02 ± 0.2</td>
<td>59.9 ± 10</td>
</tr>
</tbody>
</table>

* indicates a significant difference between monotherapy and combination therapy (P < 0.05). V_{ss}, volume of distribution at steady state.
seen when ACV is coadministered. These differences result from the decrease in AZT clearance. No statistically significant changes can be noted in the volume of distribution or maximum concentration of drug in serum ($C_{\text{max}}$) of AZT when given in the combination therapy.

The decrease in the clearance of AZT in the combination therapy group is coupled with a 60% increase in ACV clearance. Also noted is a 50% decrease in the volume of distribution of ACV when administered with AZT. It is unlikely that this can be attributed to a change in plasma protein binding, for ACV inherently has a low affinity for plasma protein binding sites (4.4 to 15.4% bound) (33). An increase in uptake of ACV by the fetus in the combination therapy may help explain this change in volume. There is a threefold increase in the amount of ACV (expressed as a percentage of dose) taken up into the fetal compartment when ACV is coadministered with AZT. The decrease in half-life of ACV in the combination therapy rats results from a decrease in volume of distribution and an increase in clearance.

Duplicate and triplicate pups were sampled at the same time point from individual pregnant rats throughout the study to ensure that each fetal sac (placenta, fetus, and amniotic fluid) had similar concentrations at any given time. No corrections were made for metabolic differences between male and female pups; however, this was not of great concern considering that neither ACV nor AZT is extensively metabolized in the rat. Low coefficients of variation were observed among fetal sacs removed at the same time point in individual dams (7.4% in fetal tissue, 6.8% in placenta, and 4.3% in amniotic fluid), indicating good reliability for this data.

The concentration-time profiles of the two drugs in amniotic fluid, placenta, and fetus are shown in Fig. 3 (AZT) and 4 (ACV), and the pharmacokinetic parameters for these matrices generated from noncompartmental analysis are tabulated in Tables 2, 3, and 4. In the rats receiving AZT alone or in combination with ACV, the initial rate of uptake in amniotic fluid and fetus is similar; however, $C_{\text{max}}$, the time to maximum concentration of drug in serum ($T_{\text{max}}$), and the AUC are higher in these tissues with the animals receiving combination therapy. A similar pattern can be seen in the placental tissue of the AZT group: a longer $T_{\text{max}}$, a higher AZT $C_{\text{max}}$, and a larger AUC are seen in the combination therapy group. For ACV (Fig. 4), no significant differences are noted in the placental concentration versus time profiles. However, both amniotic fluid and fetal exposures to ACV are much lower when ACV is given alone. An increase in the $C_{\text{max}}$ of ACV in the amniotic fluid (threefold) and the fetus (twofold) is demonstrated in the combination therapy animals. This is coupled with a shorter $T_{\text{max}}$ in both of these tissues due to a higher rate of uptake of ACV for the combination therapy group. An increase in the overall exposure of the fetal compartment to ACV in the ACV-AZT-dosed group is indicated by the twofold increase in AUC in both amniotic fluid and fetal tissue.

Relative exposure numbers are shown in Table 5. This table shows the ratios of extrapolated AUC values for each tissue to plasma AUC. For AZT, decreases in exposure to all three tissues were seen in the presence of ACV (16 to 24% decrease). This decrease suggests saturation of uptake into the fetal compartment (placenta, amniotic fluid, and fetus). On the other hand, ACV showed a threefold increase in drug exposure in amniotic fluid and fetal tissue with the combination therapy. No change in placental exposure was seen for ACV in the two therapy groups. Previous reports indicate that ACV accumulates in the amniotic fluid (17, 29). Although this may not be obvious from the concentration-versus-time profiles of ACV, the accumulation of ACV in the amniotic fluid is apparent from the prolonged half-life in this tissue (5.93 ± 3.9 h) compared to that in plasma.

The disposition of AZT and ACV in the pregnant rat was significantly altered when the two drugs were coadministered. The changes noted in the placenta and fetus suggest that transporters, in addition to passive diffusion, play a role in the uptake of both ACV and AZT in these tissues. Nucleoside, organic cation, and organic anion transporters could possibly contribute to the placental transfer of these two compounds (19, 45, 47). Interestingly, the uptake of ACV into the placenta was not affected by coadministration of AZT. However, the fetal and amniotic fluid ACV exposure was increased approximately threefold. The increase in plasma clearance coupled with an increase in fetal uptake suggests up-regulation of a transport process when ACV and AZT are coadministered.

The driving force behind the “protective effect” of AZT against ACV fetal toxicity proposed by Mamede et al. is not apparent from this study (31). The exposures to fetus and amniotic fluid of ACV are increased dramatically in the presence of AZT. However, this is not of extreme concern, con-

---

**Table 2. Pharmacokinetic parameters for amniotic fluid generated using noncompartmental analysis**

<table>
<thead>
<tr>
<th>Drug therapy</th>
<th>$C_{\text{max}}$ (mg/liter)</th>
<th>$T_{\text{max}}$ (h)</th>
<th>AUC (h · mg/liter)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACV</td>
<td>4.99 ± 2.7</td>
<td>6.20 ± 2.5</td>
<td>18.6 ± 9.3</td>
</tr>
<tr>
<td>ACV-AZT</td>
<td>10.5 ± 4.4</td>
<td>4.00 ± 1.2</td>
<td>39.6 ± 16</td>
</tr>
<tr>
<td>AZT</td>
<td>8.57 ± 2.0</td>
<td>2.33 ± 0.58</td>
<td>35.7 ± 18</td>
</tr>
<tr>
<td>AZT-ACV</td>
<td>19.6 ± 13</td>
<td>3.67 ± 0.52</td>
<td>74.1 ± 48</td>
</tr>
</tbody>
</table>

* * indicates a significant difference between monotherapy and combination therapy ($P < 0.05$).

**Table 3. Pharmacokinetic parameters for placenta generated using noncompartmental analysis**

<table>
<thead>
<tr>
<th>Drug therapy</th>
<th>$C_{\text{max}}$ (µg/g)</th>
<th>$T_{\text{max}}$ (h)</th>
<th>AUC (h · µg/g)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACV</td>
<td>34.6 ± 16</td>
<td>0.26 ± 0.3</td>
<td>82.0 ± 42</td>
</tr>
<tr>
<td>ACV-AZT</td>
<td>38.5 ± 19</td>
<td>0.12 ± 0.07</td>
<td>81.9 ± 62</td>
</tr>
<tr>
<td>AZT</td>
<td>24.2 ± 8.5</td>
<td>0.36 ± 0.3</td>
<td>72.9 ± 23</td>
</tr>
<tr>
<td>AZT-ACV</td>
<td>40.8 ± 17</td>
<td>0.68 ± 0.5</td>
<td>139 ± 62</td>
</tr>
</tbody>
</table>

**Table 4. Pharmacokinetic parameters for fetus generated using noncompartmental analysis**

<table>
<thead>
<tr>
<th>Drug therapy</th>
<th>$C_{\text{max}}$ (µg/g)</th>
<th>$T_{\text{max}}$ (h)</th>
<th>AUC (h · µg/g)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACV</td>
<td>7.89 ± 1.4</td>
<td>2.50 ± 2.0</td>
<td>37.4 ± 10</td>
</tr>
<tr>
<td>ACV-AZT</td>
<td>24.5 ± 4.7</td>
<td>0.65 ± 0.3</td>
<td>88.1 ± 27</td>
</tr>
<tr>
<td>AZT</td>
<td>28.9 ± 5.3</td>
<td>0.50 ± 0.4</td>
<td>59.4 ± 32</td>
</tr>
<tr>
<td>AZT-ACV</td>
<td>32.7 ± 15</td>
<td>1.2 ± 0.5</td>
<td>108 ± 64</td>
</tr>
</tbody>
</table>

* * indicates a significant difference between monotherapy and combination therapy ($P < 0.05$).
support the observation of an increased activity of AZT when given in this combination. However, caution should be taken with direct extrapolation of these results to humans until further investigations have been conducted with in vitro human placentas or primates.

Both ACV and AZT are known to be safe and effective against protecting unborn children against their respective viruses. This combination of drugs could allow for a potentiated activity of AZT while increasing the exposure of the fetus to ACV. Although the pharmacokinetics of each drug is altered in the combinations, therapeutic levels in plasma of each can be maintained when they are given together. However, the higher levels achieved in the fetus and dam could also increase the toxicities associated with these agents.

ACKNOWLEDGMENTS

We acknowledge the assistance of Warren Beach and Valeria Coscia for their help in extracting and recrystallizing some of the drugs used in this study from their respective pharmaceutical formulations.

REFERENCES


TABLE 5. Relative exposure (AUCtissue/AUCplasma) data (mean plus or minus standard deviation) from amniotic fluid, fetal tissue, and placental tissue generated from the noncompartmental analysis of tissue data collected from pregnant ACV monotherapy, AZT monotherapy, and ACV-AZT combination therapy rats (60 mg/kg)*

<table>
<thead>
<tr>
<th>Tissue</th>
<th>ACV</th>
<th>ACV-AZT</th>
<th>AZT</th>
<th>AZT-ACV</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fetus</td>
<td>0.20 ± 0.05</td>
<td>0.56 ± 0.2*</td>
<td>0.72 ± 0.2</td>
<td>0.59 ± 0.2</td>
</tr>
<tr>
<td>Placenta</td>
<td>0.42 ± 0.1</td>
<td>0.43 ± 0.3</td>
<td>1.00 ± 0.5</td>
<td>0.76 ± 0.2</td>
</tr>
<tr>
<td>Amniotic fluid</td>
<td>0.091 ± 0.02</td>
<td>0.26 ± 0.1*</td>
<td>0.48 ± 0.3</td>
<td>0.40 ± 0.2</td>
</tr>
</tbody>
</table>

* a * indicates a significant difference between monotherapy and combination therapy.

FIG. 4. The concentration (mean plus standard deviation) versus time profile of ACV monotherapy and in combination with AZT from amniotic fluid (a), fetus (b), and placenta (c).